Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
2d
Deepmatter, a leading innovator in digital chemistry, today unveils its rebrand to ChemAI, as part of a strategic growth plan to ...
CAMBRIDGE, Mass., November 27, 2024--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...
New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...
Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback